UK approves its second weight-loss pill while EU access lags

AI justification

[Auto-resolved by learned corrector: learned-map — A=MINT/B=MINT -> MINT (human chose this in 87% of 272 past reviews)] Approval enables innovation but risks inequitable access, violating healthcare rights under UDHR Article 25. | The UK's approval of a weight-loss drug is a positive step for public health (SDG 3), but the lack of immediate NHS coverage risks deepening health inequalities. The decision prioritizes regulatory progress over equitable access, creating a tension between innovation a